£495.00

The 2013-2018 Outlook for Cystic Fibrosis Drugs in India

Econometrics

Price data last checked 40 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 51 days · 51 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 51 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (51 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 51 days

Description

This econometric study covers the latent demand outlook for cystic fibrosis drugs across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 5,000 cities in India. For each city in question, the percent share the city is of it's state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for cystic fibrosis drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in India). This study gives, however, my estimates for the latent demand, or the P.I.E., for cystic fibrosis drugs in India. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of India. For each state or union territory, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

Product Specifications

Format: paperback
ASIN: B00E18QHZY
Category: Books > Subjects > Business, Finance & Law > Economics > Econometrics
Domain: Amazon UK
Release Date: 19 June 2013
Listed Since: 23 July 2013

The 2013-2018 Outlook for Cystic Fibrosis Drugs in India

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2011-2016 Outlook for Cystic Fibrosis Drugs in Asia & Oceana

The 2025-2030 World Outlook for Cystic Fibrosis Drugs

The 2025-2030 World Outlook for Cystic Fibrosis Therapeutics

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in India

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in the United States

The 2013-2018 Outlook for Chronic Obstructive Pulmonary Disease (COPD) Therapeutics in India

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in China

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in China

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in India

Cystic Fibrosis: Heterogeneity and Personalized Treatment

Cystic Fibrosis: Facts, Management and Advances

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments for US Zip Codes

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments for US Zip Codes

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in Japan

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in Japan

Cystic Fibrosis in the Light of New Research - Medical Book

The 2013-2018 Outlook for Non-Prescription Cough and Cold Capsules and Tablets in India

The 2025-2030 World Outlook for Idiopathic Pulmonary Fibrosis Treatments

The 2025-2030 World Outlook for Idiopathic Pulmonary Fibrosis

The 2013-2018 Outlook for Prescription Non-Narcotic Cough Preparations and Expectorants in India

The 2013-2018 Outlook for Medical Fiber Optics in India

The 2013-2018 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in India

The 2013-2018 Outlook for Non-Prescription Cough Syrups in India

The 2013-2018 Outlook for Medical Fiber Optics in North America & the Caribbean